STERIS plc Form 10-Q Summary
Business Context and Reporting Period
STERIS is a global provider of infection prevention, healthcare, applied sterilization, life sciences, and dental products and services. The filing covers the three months ended June 30, 2023, STERIS’s first quarter of fiscal 2024, compared with the three months ended June 30, 2022. The interim financial statements are unaudited and prepared under U.S. GAAP.
Reportable segments are Healthcare, Applied Sterilization Technologies (AST), Life Sciences, and Dental. The company had 98.8 million ordinary shares outstanding as of August 3, 2023.
Key Financial Metrics
| Metric | Q1 FY2024 | Q1 FY2023 | Change |
|---|---|---|---|
| Total revenue | $1,284.5 million | $1,156.5 million | 11.1% |
| Product revenue | $713.9 million | $637.1 million | 12.0% |
| Service revenue | $570.7 million | $519.4 million | 9.9% |
| Gross profit | $573.5 million | $517.8 million | 10.7% |
| Gross margin | 44.6% | 44.8% | Down 20 basis points |
| Income from operations | $188.9 million | $158.4 million | 19.2% |
| Net income attributable to shareholders | $123.6 million | $111.3 million | 11.1% |
| Diluted earnings per share | $1.25 | $1.10 | 13.6% |
| Operating cash flow | $281.1 million | $231.7 million | 21.3% |
| Free cash flow | $214.5 million | $117.1 million | 83.2% |
Interest expense increased to $32.4 million from $22.7 million, primarily because of higher interest rates on floating-rate debt. The effective tax rate rose to 21.6% from 17.9%, reflecting geographic profit mix and fewer favorable discrete tax items.
Cash dividends declared and paid were $0.47 per share, compared with $0.43 per share in the prior-year quarter. The company did not repurchase shares under its public repurchase program during the quarter.
Segment Performance
| Segment | Revenue | Year-over-year change | Operating income | Operating margin |
|---|---|---|---|---|
| Healthcare | $818.9 million | 17.2% | $198.2 million | 24.2% |
| AST | $233.1 million | 5.5% | $109.6 million | 47.0% |
| Life Sciences | $131.4 million | (0.6%) | $49.8 million | 37.9% |
| Dental | $101.2 million | (3.5%) | $22.0 million | 21.8% |
Healthcare growth was led by higher volume and pricing, including capital equipment revenue growth of 32.9%. AST was affected by customer inventory management and lower demand from bioprocessing customers. Life Sciences declined because lower capital equipment revenue exceeded service and consumables growth. Dental declined because customer inventory destocking more than offset pricing benefits.
Liquidity, Debt, and Cash Flow
- Cash and cash equivalents were $208.6 million at June 30, 2023, essentially unchanged from $208.4 million at March 31, 2023.
- Total debt was $2.924 billion, down from $3.079 billion at March 31, 2023. Long-term debt was $2.860 billion and short-term debt was $63.4 million.
- Debt-to-total capital was 32.2% at June 30, 2023, compared with 33.6% at March 31, 2023 and 31.9% at June 30, 2022.
- Borrowings under the revolving credit facility were $158.2 million, with $10.5 million of letters of credit outstanding.
- Capital expenditures were $66.6 million, compared with $115.9 million in the prior-year quarter.
- Financing cash outflows were $213.6 million, including $144.7 million of net credit-facility repayments, $15.0 million of term-loan repayments, and $46.4 million of dividends.
- Commercial commitments were approximately $110.0 million at June 30, 2023.
Material Changes Versus the Prior Comparable Period
- Revenue increased 11.1%, driven primarily by higher volume and pricing, particularly in Healthcare.
- Gross margin contracted modestly because material and labor inflation exceeded pricing benefits by approximately 20 basis points overall.
- Operating income increased 19.2%; lower acquisition and integration charges also contributed, declining to $2.7 million from $9.8 million.
- Operating cash flow and free cash flow increased substantially, aided by lower compensation-related cash payments and lower capital spending, partly offset by continued inventory investment.
- Interest expense increased because of higher floating-rate borrowing costs.
- Healthcare backlog was $491.7 million, down from $521.7 million a year earlier, reflecting stronger shipments and shorter lead times. Life Sciences backlog was $104.9 million, up from $92.7 million.
Guidance, Outlook, Risks, and Unusual Items
The filing does not provide a clear quantified full-year revenue, earnings, or cash-flow guidance. Management cited demand drivers including aging populations, increased procedures, concern over hospital-acquired infections, pharmaceutical regulatory requirements, and customer efficiency initiatives.
On August 2, 2023, after the reporting date, STERIS completed its acquisition of surgical instrumentation, laparoscopic instrumentation, and sterilization container assets from Becton, Dickinson and Company for $540.0 million. The transaction was funded entirely with additional debt. The company expects a tax benefit with an estimated present value of approximately $60.0 million, but had not completed purchase accounting for the acquired assets and liabilities as of the filing date.
- Key operating risks include inflation in materials and labor, supply-chain disruptions, raw-material availability and pricing, customer inventory destocking, regulatory requirements, product liability, litigation, foreign-exchange movements, and higher borrowing costs.
- The company uses foreign-currency forward contracts and nickel commodity swaps; these instruments are not used for speculative purposes and are not designated for hedge accounting.
- The IRS has proposed adjustments relating to deemed dividend inclusions and withholding tax that could result in an estimated cumulative liability of approximately $50.0 million. STERIS is contesting the assertions and has not recorded reserves; management does not expect a material adverse effect on consolidated financial position, although the matter could materially affect results or cash flow in a single period.
- STERIS is subject to ordinary-course litigation, investigations, product claims, tax audits, and regulatory matters. Management believes existing reserves are adequate and that pending matters will not materially affect the company overall, while acknowledging that outcomes remain uncertain.
- Disclosure controls and procedures were assessed as effective, with no material changes to internal control over financial reporting during the quarter.
Important Facts for Investors to Verify
- Whether pricing continues to offset material, labor, energy, and other inflationary pressures and how this affects gross margins.
- The effect of the August 2023 Becton, Dickinson asset acquisition on revenue, integration costs, goodwill, intangible assets, leverage, and interest expense.
- The sustainability of elevated free cash flow after inventory investment, capital expenditures, dividends, debt repayments, and acquisition funding.
- Trends in Healthcare backlog, Life Sciences capital equipment demand, AST bioprocessing demand, and Dental customer destocking.
- Future interest-rate exposure, revolving credit utilization, covenant headroom, and the company’s ability to reduce debt following the acquisition.
- The resolution and potential cash impact of the IRS tax matter and any significant litigation, regulatory, product-liability, or insurance developments.